Ajanta Pharma Ltd
NSE:AJANTPHARM
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1 879
3 426.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AJANTPHARM stock under the Base Case scenario is 1 831.68 INR. Compared to the current market price of 2 960.05 INR, Ajanta Pharma Ltd is Overvalued by 38%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Ajanta Pharma Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AJANTPHARM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Ajanta Pharma Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Ajanta Pharma Ltd
Balance Sheet Decomposition
Ajanta Pharma Ltd
Current Assets | 27.9B |
Cash & Short-Term Investments | 7.6B |
Receivables | 10.4B |
Other Current Assets | 9.9B |
Non-Current Assets | 20B |
Long-Term Investments | 340m |
PP&E | 17.9B |
Intangibles | 133.2m |
Other Non-Current Assets | 1.7B |
Current Liabilities | 9.1B |
Accounts Payable | 4.2B |
Other Current Liabilities | 4.9B |
Non-Current Liabilities | 2B |
Long-Term Debt | 215.4m |
Other Non-Current Liabilities | 1.8B |
Earnings Waterfall
Ajanta Pharma Ltd
Revenue
|
44.9B
INR
|
Cost of Revenue
|
-10.9B
INR
|
Gross Profit
|
34B
INR
|
Operating Expenses
|
-22.7B
INR
|
Operating Income
|
11.3B
INR
|
Other Expenses
|
-2.6B
INR
|
Net Income
|
8.8B
INR
|
Free Cash Flow Analysis
Ajanta Pharma Ltd
INR | |
Free Cash Flow | INR |
Ajanta Pharma reports robust financial growth, with Q2 revenue rising 15% to INR 1,187 crores. The company boasts a 14% H1 increase, driven by a 19% surge in Branded Generics. Gross margins improved to 77%, with EBITDA margins expected to hover around 28% for FY 2025. Guidance signals low-teens growth, with U.S. Generics anticipated at mid-single digits, while African operations anticipate mid-teens. PAT exhibited an 11% growth in Q2 and 15% in H1. The firm has strategically added 200 medical representatives to boost market presence, emphasizing a strong commitment to sustainable growth.
What is Earnings Call?
AJANTPHARM Profitability Score
Profitability Due Diligence
Ajanta Pharma Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Ajanta Pharma Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
AJANTPHARM Solvency Score
Solvency Due Diligence
Ajanta Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
Ajanta Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AJANTPHARM Price Targets Summary
Ajanta Pharma Ltd
According to Wall Street analysts, the average 1-year price target for AJANTPHARM is 3 019.71 INR with a low forecast of 2 000.81 INR and a high forecast of 3 848.25 INR.
Dividends
Current shareholder yield for AJANTPHARM is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AJANTPHARM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ajanta Pharma Ltd. is a holding company, which engages in the development, manufacture, and marketing of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 7,234 full-time employees. The company went IPO on 2000-06-05. The Company’s marketing network operates in domestic and international markets. The firm produces a comprehensive range of specialty products targeting different therapeutic segments for the treatment of patients, customized to each market it is present in. The branded generics business is spread in India and approximately 30 emerging countries across Africa, South-East Asia, West Asia, and The Commonwealth of Independent States (CIS). The company has product portfolio includes complex technology products. The firm has also made substantial investments in its research and development (R&D) facilities.
Contact
IPO
Employees
Officers
The intrinsic value of one AJANTPHARM stock under the Base Case scenario is 1 831.68 INR.
Compared to the current market price of 2 960.05 INR, Ajanta Pharma Ltd is Overvalued by 38%.